Literature DB >> 27790460

Blonanserin - A Novel Antianxiety and Antidepressant Drug? An Experimental Study.

Ramchandra Prabhakar Limaye1, Aditi Nitin Patil2.   

Abstract

INTRODUCTION: Many psychiatric disorders show signs and symptoms of anxiety and depression. A drug with both, effects and lesser adverse effects is always desired. Blonanserin is a novel drug with postulated effect on anxiety and depression. AIM: The study was aimed to evaluate the effect of Blonanserin on anxiety and depression in animal models.
MATERIALS AND METHODS: By using elevated plus maze test and forced swimming test, the antianxiety and antidepressant effects were evaluated. Animal ethics protocols were followed strictly. Total 50 rats (10 rats per group) were used for each test. As a control drug diazepam and imipramine were used in elevated plus maze and forced swimming test respectively. Blonanserin was tested for 3 doses 0.075, 0.2 and 0.8mg. These doses were selected from previous references as well as by extrapolating human doses.
RESULTS: This study showed an antianxiety effect of Blonanserin comparable to diazepam, which was statistically significant. Optimal effect was observed with 0.075mg, followed by 0.2 and 0.8mg. It also showed an antidepressant effect which was statistically significant. Optimal effect was observed at 0.2mg dose.
CONCLUSION: The results showed that at a dose range of 0.075 and 0.2mg Blonanserin has potential to exert an adjuvant antianxiety and antidepressant activity in animal models. In order to extrapolate this in patient, longer clinical studies with comparable doses should be planned. The present study underlines potential of Blonanserin as a novel drug for such studies.

Entities:  

Keywords:  Antipsychotic; Anxiety; Atypical; Depression

Year:  2016        PMID: 27790460      PMCID: PMC5071960          DOI: 10.7860/JCDR/2016/19347.8530

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  40 in total

1.  Anxiety-like behavior in rats: a computational model.

Authors:  C Salum; S Morato; A C Roque-da-Silva
Journal:  Neural Netw       Date:  2000-01

2.  Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.

Authors:  Takeshi Ochi; Masato Sakamoto; Akira Minamida; Kenji Suzuki; Tomohiko Ueda; Teruaki Une; Hiroshi Toda; Kazuya Matsumoto; Yoshiaki Terauchi
Journal:  Bioorg Med Chem Lett       Date:  2005-02-15       Impact factor: 2.823

3.  Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites.

Authors:  A L Johnston; S E File
Journal:  Pharmacol Biochem Behav       Date:  1989-01       Impact factor: 3.533

4.  The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice.

Authors:  M Kurt; A C Arik; S Celik
Journal:  J Basic Clin Physiol Pharmacol       Date:  2000

5.  Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.

Authors:  Jaewon Yang; Won-Myong Bahk; Hyun-Sang Cho; Yang-Whan Jeon; Duk-In Jon; Hee-Yeon Jung; Chan-Hyung Kim; Hee-Cheol Kim; Yong-Ku Kim; Young-Hoon Kim; Jun-Soo Kwon; Sang-Yeol Lee; Seung-Hwan Lee; Jung-Seo Yi; Bo-Hyun Yoon; Seung-Hyun Kim
Journal:  Clin Neuropharmacol       Date:  2010-07       Impact factor: 1.592

Review 6.  [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].

Authors:  Tadashi Ishibashi; Hiroyuki Nishikawa; Teruaki Une; Hiroshi Nakamura
Journal:  Nihon Yakurigaku Zasshi       Date:  2008-12

7.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

8.  Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze.

Authors:  J C Cole; R J Rodgers
Journal:  Pharmacol Biochem Behav       Date:  1995-11       Impact factor: 3.533

9.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

10.  Profile of blonanserin for the treatment of schizophrenia.

Authors:  Tomomi Tenjin; Seiya Miyamoto; Yuriko Ninomiya; Rei Kitajima; Shin Ogino; Nobumi Miyake; Noboru Yamaguchi
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.